Avidicure is a biotechnology company pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality, “AVC-Boosters,” designed to safely deliver targeted and potent immune-modulating monotherapy for cancer patients. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and antibody-drug conjugates (ADCs). AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of the innate and adaptive immune system. Avidicure is based the Netherlands and supported by a syndicate of top-tier investors led by EQT-LS.
